Emend (fosaprepitant) injection — CareFirst (Caremark)
prevention of nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy
Initial criteria
- For nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy, ALL of the following must be met:
- • The request is NOT for Varubi (rolapitant).
- • The requested drug will be used in combination with other antiemetic agents.
- For postoperative nausea and vomiting:
- • The request is for aprepitant capsules.
Approval duration
6 months